Another selective c-Met inhibitor, tivantinib, also showed promising results in a phase I study in patients with advanced solid tumors, including 19 with melanoma patients; Another phase I study was carried out with tepotinib in 149 patients with advanced solid tumors [98,99]. This evidence concerns the gene MET and melanoma.